Eton Pharmaceuticals (ETON) investor relations material

Executive summary

• Q1 2026 product sales reached $24.3 million, up 73% year-over-year, driven by strong growth across the rare disease portfolio and new product launches, including DESMODA and HEMANGEOL.

• Gross profit rose to $14.7 million, up 49% year-over-year, reflecting higher sales volume and favorable product mix.

• Net income was $1.6 million, reversing a $1.6 million loss in the prior year; non-GAAP net income was $4.5 million.

• Raised full-year 2026 revenue guidance to exceed $120 million, up from $110 million, reflecting strong Q1 performance and positive trends.

• Adjusted EBITDA for Q1 was $5.7 million (24% of revenue), with expectations to surpass 30% margin for the full year and targeting 50% by 2028.

Financial highlights

• Q1 2026 revenue increased 40% to $24.3 million from $17.3 million in Q1 2025; product and royalty revenue rose 73% to $24.3 million.

• Gross profit was $14.7 million, with adjusted gross profit at $16.2 million (67% of revenue).

• Net income per share was $0.06 (basic) and $0.05 (diluted); non-GAAP EPS was $0.14.

• Generated $7.4 million in operating cash flow, paid $14 million for HEMANGEOL, ending Q1 with $19.7 million in cash.

• Operating expenses increased to $12.3 million in Q1 2026, mainly due to higher R&D and G&A costs.

Outlook and guidance

• Full-year 2026 revenue expected to exceed $120 million, driven by new launches and portfolio outperformance.

• Adjusted EBITDA margin expected above 30% for 2026, with a long-term goal of 50% by 2028.

• Adjusted gross margin for 2026 expected to exceed 70%.

• Long-term targets: $200 million annual revenue run rate by end of 2027 and $500 million by 2030.

• Ongoing investments in late-stage development candidates and label expansions are anticipated to drive long-term growth.